ReviewCurrent oncology reports2021
ROS1 Targeted Therapies: Current Status.
Review in Current oncology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 49 citations in OpenAlex.
- [Clinicopathological Characteristics of ROS1-positive Non-small Cell Lung Cancer Based on Next-generation Sequencing].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Article
- Research progress of small molecule targeted drugs for non-small cell lung cancer.Frontiers in oncology · 2026Review
- Immunohistochemistry in intrahepatic cholangiocarcinoma: histological subtyping and drug selection.Frontiers in oncology · 2025Review
- A Comprehensive Review of Advances in Molecular Mechanisms and Targeted Therapies for the Specific Type of Cystic Lung Cancer.OncoTargets and therapy · 2025Review
- MET targeted therapy in non-small cell lung cancer patients withTranslational lung cancer research · 2024Article
- Current treatment and novel insights regarding ROS1-targeted therapy in malignant tumors.Cancer medicine · 2024Review
- Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, RET fusions and MET exon 14 skipping in NSCLC.Virchows Archiv : an international journal of pathology · 2024Article
- Recent advances in molecular targeted therapy of lung cancer: Possible application in translation medicine.Iranian journal of basic medical sciences · 2024Review
- Remarkable response to third-generation EGFR-TKI plus crizotinib in a patient with pulmonary adenocarcinoma harboring EGFR and ROS1 co-mutation: a case report.Frontiers in oncology · 2024Article
- ROS1 kinase inhibition reimagined: identifying repurposed drug via virtual screening and molecular dynamics simulations for cancer therapeutics.Frontiers in chemistry · 2024Article
- KLC1-ROS1 Fusion Exerts Oncogenic Properties of Glioma Cells via Specific Activation of JAK-STAT Pathway.Cancers · 2023Article
- Emerging therapeutics and evolving assessment criteria for intracranial metastases in patients with oncogene-driven non-small-cell lung cancer.Nature reviews. Clinical oncology · 2023Review
- RareWorld journal of clinical cases · 2023Article
- Review
- The landscape of actionable genomic alterations in lung adenocarcinomas in India.Frontiers in genetics · 2023Article
- Importance ofCancer drug resistance (Alhambra, Calif.) · 2023Review
- Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies.Exploration of targeted anti-tumor therapy · 2023Review
- Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance.International journal of molecular sciences · 2022Review
- ADK-VR2, a cell line derived from a treatment-naïve patient withTranslational lung cancer research · 2022Article
- Immunotherapy in Non-Small-Cell Lung Cancer Patients with Driver Alterations: A New Strategy?Cells · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewMolecular drivers are increasingly identified as therapeutic targets for non-small cell lung cancer (NSCLC). This review focuses on the role of ROS1 inhibitors in treating relapsed/metastatic ROS-1 altered (ROS1+) NSCLC. RECENT
findingsFour FDA-approved drugs have significant activity against ROS1+ NSCLC: crizotinib, ciritinib, lorlatinib, and entrectinib. Each drug yields an overall response rates exceeding 60% with ciritinib, lorlatinib, and entrectinib possessing intracranial activity. The drugs have manageable toxicity profiles. ROS1 alterations are rare molecular drivers of NSCLC that can be effectively treated with a variety of ROS1-targetd drugs. New agents are being identified that may treat resistance mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.